Hetacillin
Chemical compound
- J01CA18 (WHO)
- US: ℞-only
- (2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- 3511-16-8
Y
- 443387
- DB00739 Y
- 391616
N
- TN4JSC48CV
- D01074 N
- ChEMBL1201116 N
- DTXSID4023121
- Interactive image
- CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N3C(=O)[C@H](NC3(C)C)c4ccccc4)C(=O)O)C
InChI
- InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1N
- Key:DXVUYOAEDJXBPY-NFFDBFGFSA-NN
N
Y (what is this?) (verify)Hetacillin is a beta-lactam antibiotic that is part of the aminopenicillin family. It is a prodrug and has no antibacterial activity itself,[1] but quickly splits off acetone in the human body to form ampicillin,[2] which is active against a variety of bacteria.
Administration
Hetacillin can be administered orally. The potassium salt, hetacillin potassium, is administered by injection, either intravenously[3] or intramuscularly.[4] It is sold under the trade name Hetacin for intramammary injection in veterinary use.[5]
Hetacillin was withdrawn from the market for human use when the discovery was made that it had no advantages over ampicillin.[6]
Chemistry
Hetacillin is prepared from ampicillin and acetone. In aqueous solutions it is unstable, with a half life of 15 to 30 minutes at 37 °C (99 °F) and pH 7, quickly releasing acetone again.[7]
As opposed to ampicillin, hetacillin is only marginally broken down by the bacterial enzyme beta-lactamase, at least in vitro.[citation needed]
References
- ^ "Hetacillin". Drugbank.
- ^ Sutherland R, Robinson OP (June 1967). "Laboratory and pharmacological studies in man with hetacillin and ampicillin". British Medical Journal. 2 (5555): 804–8. doi:10.1136/bmj.2.5555.804. PMC 1843140. PMID 5182358.
- ^ Tsuji Y, Tomita M (August 1970). "[Clinical effect of intravenous injection of potassium hetacillin (Versapen 'Bristol') on pre- and post-operative infections] (in Japanese)". The Japanese Journal of Antibiotics. 23 (4): 400–2. PMID 5312791.
- ^ Hara M, Takemoto S, Kawazu T (December 1970). "[Therapeutic experience with intramuscular injection of hetacillin (Versapen 'Bristol') in infection in children] (in Japanese)". The Japanese Journal of Antibiotics. 23 (5): 482–6. PMID 5314634.
- ^ Hetacin-K Intramammary Infusion for Veterinary Use
- ^ Smith JT, Hamilton-Miller J (1970). "Hetacillin: A Chemical and Biological Comparison with Ampicillin". Chemotherapy. 15 (6): 366–78. doi:10.1159/000220703. PMID 5514976.
- ^ Faine S, Harper M (January 1973). "Independent antibiotic actions of hetacillin and ampicillin revealed by fast methods". Antimicrobial Agents and Chemotherapy. 3 (1): 15–8. doi:10.1128/aac.3.1.15. PMC 444353. PMID 4597707.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
| Glycopeptides Lipoglycopeptides |
|
|---|---|
| Lipopeptides |
|
| Polymyxins |
|
| Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
